| Literature DB >> 36250103 |
Mateus V de Castro1, Monize V R Silva1, Flávia B Soares1,2, Vivian R Cória1, Michel S Naslavsky1,2, Marilia O Scliar1,2, Erick C Castelli3, Jamile R de Oliveira4,5, Greyce L Sasahara5, Keity S Santos4,5,6, Edecio Cunha-Neto4,5,6, Jorge Kalil4,5,6, Mayana Zatz1,2.
Abstract
Background: The influence of the host genome on coronavirus disease 2019 (COVID-19) susceptibility and severity is supported by reports on monozygotic (MZ) twins where both were infected simultaneously with similar disease outcomes, including several who died due to the SARS-CoV-2 infection within days apart. However, successive exposures to pathogens throughout life along with other environmental factors make the immune response unique for each individual, even among MZ twins. Case presentation and methods: Here we report a case of a young adult monozygotic twin pair, who caught attention since both presented simultaneously severe COVID-19 with the need for oxygen support despite age and good health conditions. One of the twins, who spent more time hospitalized, reported symptoms of long-COVID even 7 months after infection. Immune cell profile and specific responses to SARS-CoV-2 were evaluated as well as whole exome sequencing.Entities:
Keywords: COVID-19; SARS-CoV-2; genetic variants; immunity; monozygotic twins
Year: 2022 PMID: 36250103 PMCID: PMC9558815 DOI: 10.3389/fmed.2022.1008585
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
FIGURE 1Clinical timeline of the major events of the twins’ case.
PBMCs immunophenotyping of the twin volunteers, 7 months after COVID-19 episode.
| ID | CD3 + T-cells | CD4 + T-cells | CD8 + T-cells | Monocytes | NK cells | B-cells |
| 01 | 56.2 | 63.5 | 31.1 | 7.7 | 8.9 | 9.3 |
| 02 | 57.5 | 57.7 | 35.3 | 8.0 | 8.8 | 7.7 |
| Healthy | 45–70 | 25–60 | 5–30 | 10–30 | 5–10 | 5–15 |
*Reference parameters values for individuals in the same age range (15).
FIGURE 2Global immune profiling of the twin volunteers, 7 months after the COVID-19 episode. (A,B) Type I/III IFN production by PBMCs after toll-like receptor (TLR) stimulus. (C,D) IFN-γ and IL-2 production by PBMC when stimulated by SARS-CoV-2 peptides. (E) Serological assays for SARS-CoV-2 IgA, IgG, and IgM through ELISA for the receptor-binding domain (RBD) and nucleocapsid protein (NP).
Blood test parameters of the volunteers, 7 months after the COVID-19 episode.
| Variables | ID 01 | ID 02 | Reference values |
|
| |||
| Erythrocyte/red blood cell (RBC) count (millions/mm3) | 4.64 | 4.57 | 4.30–5.70 |
| Hemoglobin concentration (g/dL) | 14.8 | 14.1 | 13.5–17.5 |
| Hematocrit (%) | 42.0 | 42.0 | 39.0–50.0 |
| Mean cell/corpuscular volume—MCV (μ3) | 90.5 | 91.9 | 81.2–95.1 |
| Mean cell hemoglobin—MCH (%) | 31.9 | 30.9 | 26.0–34.0 |
| Mean cell hemoglobin concentration—MCHC (pg) | 35.2 | 33.6 | 31.0–36.0 |
| RBC distribution width—RDW (%) | 11.6 | 11.3 | 8.0–15.5 |
| Erythrocyte sedimentation rate—ESR (mm/1 h) |
|
| 0–6 |
|
| |||
| Leukocyte/white blood cell (WBC) count/mm3 | 4,310 | 4,840 | 3,500–10,500 |
| Neutrophil count/mm3 | 2,030.01 | 2,574.88 | 1,700.00–8,400.00 |
| Eosinophil count/mm3 | 349.11 | 208.12 | 50.00–420.00 |
| Basophil count/mm3 | 60.34 | 48.40 | 0.00–105.00 |
| Lymphocyte count/mm3 | 1,560.22 | 1,669.80 | 900.00–3,150.00 |
| Monocyte count/mm3 | 310.32 | 338.80 | 140.00–1,260.00 |
|
| |||
| Platelet count/mm3 | 311,000 | 304,000 | 140,000–400,000 |
| Prothrombin time (s) | 10.2 | 10.6 | 9.6–12.0 |
| Activated partial thromboplastin time—APTT (s) | 32.5 | 32.1 | 22.7–32.5 |
| D dimer (μg/mL) | 0.15 | 0.17 | 0–0.50 |
|
| |||
| C-reactive protein—CRP (mg/dL) | 0.12 | 0.14 | 0–0.60 |
| Ferritin (ng/mL) | 331.0 |
| 25.0–400.0 |
| Lactate dehydrogenase—LDH (U/L) | 193 | 198 | 0–250 |
|
| |||
| B-type natriuretic peptide–BNP (pg/mL) | <5 | <5 | <100 |
| Troponin T (ng/mL) | <0.003 | 0.003 | 0.000–0.030 (negative) |
| Creatine phosphokinase—CPK (U/L) | 186 |
| 0–190 |
| Glutamic-oxaloacetic transaminase—GOT (U/L) | 34 | 28 | 0–50 |
| Glutamic pyruvic transaminase—GPT (U/L) | 47 | 33 | 0–50 |
| Urea (mg/dL) | 27 | 28 | 10–50 |
| Creatinine (mg/dL) | 0.8 | 0.9 | 0.7–1.2 |
The parameters out of the reference values were highlighted in red.